The clininical value of vascular endothelial growth factor (VEGF) in the development of lung sarcoidosis. Source: International Congress 2018 – Sarcoidosis: from basic research to patient outcomes Year: 2018
A role for vascular endothelial growth factor (VEGF) in fibrosis? Source: Annual Congress 2009 - From emphysema to fibrosis: mechanisms of cellular remodelling in the diseased lung Year: 2009
Investigating new prognostic crossroads in lung carcinomas; comparing the prognostic potential of vascular endothelial growth factor (VEGF) and its receptors versus endoglin (CD105) Source: Annual Congress 2009 - Hot topics in molecular pathology and functional genomics of lung cancer Year: 2009
Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) as a prognostic factor of survival in patients with lung adenocarcinoma Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008
Elevation of circulating endothelial cell levels in lung cancer – a new prognostic and/or predictive marker? Source: Annual Congress 2008 - Diagnosis and prognosis in thoracic oncology Year: 2008
Serum levels of vascular endothelial growth factor in the differential diagnosis of pulmonary tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 210s Year: 2002
Bioavailability of vascular endothelial growth factor (VEGF)? A role in pulmonary fibrosis? Source: Annual Congress 2012 - Fibrogenesis between epithelial injury and fibroblast proliferation Year: 2012
The serum levels of endothelin (ET-1); an activation marker and prognostic indicator in sarcoidosis? Source: Eur Respir J 2005; 26: Suppl. 49, 80s Year: 2005
Serum levels of vascular endothelial growth factor in lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004
Serum levels of vascular endothelial growth factor (VEGF) are elevated in patients with acute exacerbated COPD Source: Eur Respir J 2005; 26: Suppl. 49, 350s Year: 2005
A soluble adhesion molecule ‘E-selectin‘; an activation marker and prognostic indicator in sarcoidosis? Source: Eur Respir J 2005; 26: Suppl. 49, 685s Year: 2005
Serum levels of vascular endothelial growth factor in patients with active pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 341s Year: 2006
Concentration of serum vascular endothelial growth factor D and its correlation with functional and clinical variables in patients with lymphangioleiomyomatosis from a Brazilian reference centre Source: International Congress 2017 – Rare diseases Year: 2017
Changes and significance of hepatoma-derived growth factor and vascular endothelial growth factor in serum and lung tissue from patients with lung cancer Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Increased binding activity of hypoxia inducible factor (HIF)-1α to vascular endothelial growth factor (VEGF) promoter region mediates enhanced vascular permeability in the lung of cystic fibrosis (CF) patients Source: Eur Respir J 2003; 22: Suppl. 45, 173s Year: 2003
Production of a novel isoform of vascular endothelial growth factor (VEGF) by the normal human lung Source: Eur Respir J 2006; 28: Suppl. 50, 822s Year: 2006
Vascular endothelial growth factor (VEGF) is a predictable marker for FEV1 progression in patients with Lymphangiolyomyomatosis (LAM). Source: International Congress 2019 – Innovative approaches for management and treatment of rare diffuse parenchymal lung diseases Year: 2019
The role of serum adhesion molecules and vascular endothelial growth factor in the treatment approach of the lung cancer patients Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009
Vascular endothelial growth factor and tumor necrosis factor gene polymorphisms in Turkish patients with sarcoidosis Source: Eur Respir J 2006; 28: Suppl. 50, 353s Year: 2006